# Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

> **NCT00384215** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 352 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin glargine [rDNA origin] injection

## Key facts

- **NCT ID:** NCT00384215
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 352 (—)
- **Last updated:** 2011-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384215, "Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00384215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*